Toll Free: 1-888-928-9744

Periodontitis - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Periodontitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Periodontitis - Pipeline Review, H1 2017, provides an overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape.

Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Periodontitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Periodontitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Periodontitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Periodontitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Periodontitis (Mouth And Dental Disorders).
- The pipeline guide reviews pipeline therapeutics for Periodontitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Periodontitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Periodontitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Periodontitis (Mouth And Dental Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Periodontitis (Mouth And Dental Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Periodontitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Periodontitis - Overview Periodontitis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Periodontitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Periodontitis - Companies Involved in Therapeutics Development Amyndas Pharmaceuticals LLC C3J Therapeutics Inc CSL Ltd Ensol Biosciences Inc Geistlich Pharma AG Kaken Pharmaceutical Co Ltd Periodontitis - Drug Profiles AMY-101 - Drug Profile Product Description Mechanism Of Action R&D Progress Drug to Antagonize C5aR for Periodontitis - Drug Profile Product Description Mechanism Of Action R&D Progress GM-0111 - Drug Profile Product Description Mechanism Of Action R&D Progress Hesed-3000 - Drug Profile Product Description Mechanism Of Action R&D Progress PODCRC-OHS - Drug Profile Product Description Mechanism Of Action R&D Progress R-10001 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Periodontitis - Drug Profile Product Description Mechanism Of Action R&D Progress ST-266 - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides for Periodontitis - Drug Profile Product Description Mechanism Of Action R&D Progress taurolidine - Drug Profile Product Description Mechanism Of Action R&D Progress trafermin - Drug Profile Product Description Mechanism Of Action R&D Progress Periodontitis - Dormant Projects Periodontitis - Discontinued Products Periodontitis - Product Development Milestones Featured News & Press Releases Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis Oct 01, 2015: Kaken Submits a New Drug Application for "KCB-1D", Medicinal Product for Periodontal Regeneration May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Periodontitis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H1 2017 Periodontitis - Pipeline by C3J Therapeutics Inc, H1 2017 Periodontitis - Pipeline by CSL Ltd, H1 2017 Periodontitis - Pipeline by Ensol Biosciences Inc, H1 2017 Periodontitis - Pipeline by Geistlich Pharma AG, H1 2017 Periodontitis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017 Periodontitis - Dormant Projects, H1 2017 Periodontitis - Discontinued Products, H1 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify